Affinity Biosciences

[On Demand]
Search General Info
Search Education
Search Partnering Companies
A novel breakthrough antibody discovery platform that enables the discovery of antibodies that can target peptides from intracellular proteins presented on the the cell surface by MHC. Targeting peptide MHC complexes (pMHC) with TCR-like or TCR-mimic antibodies has proven very challenging with only very limited success. Affinity's platform has consistently worked against this target opening up a vast array of new targets for oncology, antiviral and autoimmune indications.
Affinity's antibodies have been shown to be highly selective and able to kill cancer cells in vitro and in vivo in CAR-T and bispecific formats. Affinity has been collaborating with U Penn (neoantigens including KRAS), the Children's Hospital of Philadelphia (neuroblastoma), NIH (RCC) and other top insitutions.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
CAR-T for neuroblastoma
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Affinity Biosciences Pty Ltd